Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.61 |
| ▸ | NOS3 | P29474 | 3/20 | 0.61 |
| ▸ | NOS1 | P29475 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064145 | 1.00 | NOS2 (0.61) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL32677087 | 1.00 | NOS2 (0.61) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL17070606 | 1.00 | NOS2 (0.61) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL16879113 | 0.90 | NOS2 (0.65) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL16879114 | 0.90 | NOS2 (0.65) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL18765748 | 0.89 | ALDH1A1 (0.54) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL4850176 | 0.89 | ALDH1A1 (0.54) | NOS2NOS3NOS1CA12CA7 | |
| SCHEMBL32677046 | 0.88 | ATM (0.60) | NOS2NOS3NOS1ATML3MBTL1 | |
| SCHEMBL21415517 | 0.88 | ATM (0.60) | NOS2NOS3NOS1ATML3MBTL1 | |
| SCHEMBL20028165 | 0.88 | ATM (0.60) | NOS2NOS3NOS1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| CN-112094259-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2015134923-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | NOS2 2405/4885NOS3 2234/4885NOS1 2463/4885 |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | NOS2 1823/4885NOS3 1741/4885NOS1 774/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | NOS2 1823/4885NOS3 1741/4885NOS1 774/4885 |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | TPO, FLI1, SSTR3 | NOS2 3123/4885NOS3 2085/4885NOS1 3955/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | NOS2 4481/4885NOS3 4038/4885NOS1 4367/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | NOS2 1812/4885NOS3 1782/4885NOS1 771/4885 |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | TPO, FLI1, SSTR3 | NOS2 3123/4885NOS3 2085/4885NOS1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.